SIGA Therapeutics (NASDAQ:SIGA) has dropped 32% in late Friday afternoon trading after a U.S. FDA monkeypox update stated that the company smallpox antiviral Tpoxx (tecovirimat) has not demonstrated efficacy or safety in human studies.
Buy the dip?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
